Anti-Human TNF Therapeutic Antibody (Adalimumab)
Recombinant monoclonal antibody to Respiratory syncytial virus TNF. Adalimumab (HUMIRA, AbbVie) is the third TNF inhibitor, after infliximab and etanercept. Like infliximab and etanercept, adalimumab binds to Tumor necrosis factor-alpha (TNFα), preventing it from activating TNF receptors. Adalimumab was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein. TNFα inactivation has proven to be important in downregulating the inflammatory reactions associated with autoimmune diseases. adalimumab is for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012 by the FDA in the disease's management, it has been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's Disease.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-010 |
| Pricing | Inquiry |
| Host | Human |
| Target | TNF |
| Species Reactivity | Human |
| Type | IgG1 - kappa |
| Applications | Suitable for use in ELISA, IP, FC, FuncS, Neut, IF, IHC and most other immunological methods. |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |